Bridging unter Antikoagulation und Thrombozytenaggregationshemmung

Abstract

When bridging anticoagulation, the risk of bleeding - compared to the thromboembolic risk - is often underestimated. Bridging is only indicated in case of high (and possibly moderate) thromboembolic risk. When bridging patients with indication for dual antiplatelet therapy, an interdisciplinary case discussion should take place to assess the risk.